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Abstract
Cytotoxic T lymphocytes (CTL) provide protection against pathogens and tumors. In addition, experiments in mouse models
have shown that CTL can also kill antigen-presenting dendritic cells (DC), reducing their ability to activate primary and
secondary CD8
+ T cell responses. In contrast, the effects of CTL-mediated killing on CD4
+ T cell responses have not been
fully investigated. Here we use adoptive transfer of TCR transgenic T cells and DC immunization to show that specific CTL
significantly inhibited CD4
+ T cell proliferation induced by DC loaded with peptide or low concentrations of protein antigen.
In contrast, CTL had little effect on CD4
+ T cell proliferation induced by DC loaded with high protein concentrations or
expressing antigen endogenously, even if these DC were efficiently killed and failed to accumulate in the lymph node (LN).
Residual CD4
+ T cell proliferation was due to the transfer of antigen from carrier DC to host APC, and predominantly
involved skin DC populations. Importantly, the proliferating CD4
+ T cells also developed into IFN-c producing memory cells,
a property normally requiring direct presentation by activated DC. Thus, CTL-mediated DC killing can inhibit CD4
+ T cell
proliferation, with the extent of inhibition being determined by the form and amount of antigen used to load DC. In the
presence of high antigen concentrations, antigen transfer to host DC enables the generation of CD4
+ T cell responses
regardless of DC killing, and suggests mechanisms whereby CD4
+ T cell responses can be amplified.
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Introduction
DC are potent APC that play critical roles in cross-presentation
[1] and the differentiation of naı ¨ve CD8
+ T cell into CTL [2]. The
development and accumulation of CTL are crucial in controlling
and resolving bacterial and viral infections. Pathogen eradication
and the pre-determined numerical contraction of specific CTL
eventually lead to resolution of the ongoing immune response [3].
The clearance of APC may also contribute to regulating
immune responses. Experimental evidence indicates that APC, in
particular DC, are targeted and killed by CTL, regulatory T cells,
or NK cells [4,5,6]. Peptide-specific CTL induced by DC
immunization or viral infection in vivo [5,7], or adoptively
transferred T cells activated in vitro [8] were shown to eliminate
antigen-loaded DC in vivo. Live imaging of mouse LN confirmed
that effector and memory CTL can establish interactions with
cognate antigen-loaded DC, and induce DC apoptosis [9]. CTL-
mediated killing of DC in turn results in reduced CD8
+ T cell
expansion and anti-tumor immune responses [5,9,10], or can
modify the phenotype of alloreactive T cell responses [11].
Elimination of DC by regulatory T cells or NK cells was also
shown to limit the DC’s ability to interact with CD4
+ and CD8
+ T
cells, and induce their productive activation [4,12]. Conversely,
prolonged DC survival may result in enhanced T cell proliferation,
inflammation, and autoimmune manifestations [13,14].
It has been proposed that the physiological function of CTL-
mediated DC killing is to act as a negative feedback mechanism on
CD8
+ T cell immune responses [9,11,15]. Antigen presentation to
naı ¨ve and/or memory CD8
+ T cells in the LN, and their
consequent further expansion, may be unnecessary if effector CTL
are already present in the periphery to clear incoming insults. In
this scenario the removal of antigen-presenting DC by CTL would
be beneficial by preventing redundant T cell expansion [10].
However, it is unclear whether such a regulatory mechanism
affects CD4
+ as well as CD8
+ T cells, given that they are initiated
by different DC subpopulations [1] and are subject to different
regulatory mechanisms.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37481In this article we examine the impact of CTL-mediated DC
killing on CD4
+ T cell responses. We show that proliferation of
CD4
+ T cells was affected by DC killing, and that this was
dependent on the amount and form of antigen used to load DC.
When antigen presentation remained restricted to the injected
DC, CD4
+ T cell proliferation was inhibited by CTL. In contrast,
in conditions where antigenic material was transferred from the
injected DC to host DC, CD4
+ T cell proliferation, memory
differentiation and ability to produce IFN-c were maintained.
Therefore, our findings show that inter-DC antigen transfer can
influence the size and quality of T cell responses, and suggest
antigen transfer as a mechanism to overcome CTL-mediated DC
killing.
Results
The method of antigen loading affects the sensitivity of
DC to CTL-mediated killing, and their ability to
accumulate in the draining LN (dLN)
We have reported that effector CTL eliminate DC in vivo and
prevent their accumulation in the dLN [5]. We used DC from
bone marrow (BM) cultures to show that both 5-(and 6)-
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled
DC loaded with SIINFEKL (SIINFEKL-DC) and Cell Tracker
Orange (CTO)-labelled DC not loaded with peptide (DC-only)
accumulated in the dLN of naı ¨ve mice in equal proportions
(Figure 1A). In contrast, the CFSE
+ SIINFEKL-loaded DC
population was selectively depleted in the dLN of mice that had
been injected intravenously (i.v.) with in vitro activated OT-I CTL
24 h before DC administration. A similar depletion was also
observed in C57BL/6 mice that had been immunized to prime an
endogenous CTL response [5,7,8,16], indicating that killing of DC
can occur in the context of a physiological immune response and
does not require CTL transfer.
Peptide incubation is not a physiological method of antigen
loading. We therefore tested the sensitivity of DC to CTL-
mediated killing using other methods of OVA loading. OVA-
transgenic (OVAtg) DC endogenously expressing OVA [17] were
eliminated by OT-I CTL as effectively as SIINFEKL-DC
(Figure 1B). DC loaded with OVA protein (OVA-DC) at 2 mg/
ml, a high dose that is required to obtain cross-presentation by BM
DC, were only partially killed by specific CTL (Figure 1C). This
reduced killing was not due to the protective effect of CD4
+ T cells
recognizing OVA in the context of MHCII on DC [18,19], as
both C57BL/6 wild type (WT) and MHCII
2/2 DC were
susceptible to CTL killing (Figure 1C). Reduced killing was also
not due to some DC not taking up OVA protein, as experiments
using fluorochrome-labelled OVA showed that at least 90% of the
DC had taken up fluorescent label (not shown). Instead, reduced
killing appeared to be due to the relatively inefficient cross-
presentation of OVA protein by BM DC, as OVA-DC could
induce OT-I proliferation in vitro but gave a low to undetectable
signal when examined for expression of MHCI/SIINFEKL
complexes by staining with the 25-D1 antibody [20] and flow
cytometry (not shown). We conclude that the method of antigen
loading influences the susceptibility of DC to CTL-mediated
killing, presumably by determining the efficiency of MHCI/
SIINFEKL complex formation.
CD4
+ T cell proliferation in the LN does not require direct
presentation by injected DC
By preventing the accumulation of antigen-presenting DC in
the dLN, CTL might also inhibit the subsequent induction of
CD4
+ T cell responses. We therefore evaluated the ability of
specific CTL to inhibit the division of CFSE-labelled OT-II cells
after DC immunization. In all experiments, OT-II T cell division
was examined in the dLN 3 days after DC immunization; no
division was observed in unimmunized mice, or mice immunized
with DC only (not shown).
Injection of DC loaded with SIINFEKL+OVA323–339 induced
vigorous OT-II T cell proliferation, but this was reduced to
background levels by transfer of OT-I CTL (Figure 2A), indicating
that CTL-mediated killing of DC reduced the availability of
immunostimulatory antigen in the dLN. Strong OT-II T cell
proliferation was also observed in mice immunized with OVAtg
DC (Figure 2B), which are highly sensitive to CTL-mediated
killing. Again, the percentage of divided OT-II T cells was lower in
mice injected with CTL, however, substantial proliferation was
still observed and the number of divided OT-II T cells did not
significantly differ between untreated and CTL-treated mice
(Figure 2B). This result suggests that OVA antigen was still
available in the dLN, even when the number of OVAtg DC was
decreased to low or undetectable levels due to the presence of
specific CTL (Figure 1B).
We then examined OT-II proliferation after immunization with
OVA-DC. As shown in Figure 2C, OT-I CTL transfer did not
affect the percentage or number of proliferating OT-II cells in
dLN. This was not only due to suboptimal killing of OVA-DC by
CTL, as simultaneous loading of DC with OVA protein and
SIINFEKL led to almost complete killing of DC by CTL (not
shown), but did not completely eliminate the proliferation of OT-
II cells in the dLN (Figure 2D, compare to Figure 2A).
The results in Figure 2B and 2C suggested that OT-II cell
proliferation may not require direct presentation of OVA by
injected DC. To assess this possibility, we immunized mice with
MHCII
2/2 DC loaded with OVA protein, as these DC are
unable to directly present antigen to OT-II cells. Robust OT-II
cell proliferation was observed in mice immunized with OVA-
MHCII
2/2 DC, although the number of divided cells in the dLN
was lower than in mice immunized with WT DC (Figure 2C). OT-
I CTL transfer did not affect this division. OT-II cell proliferation
was also observed in mice immunized with MHCII
2/2 DC loaded
with SIINFEKL+2 mg/ml OVA protein (Figure 2D); interesting-
ly, this proliferation was comparable to the proliferation induced
by WT DC in the presence of CTL. Together with the data in
Figure 2B, these results suggest that antigenic material can be
transferred from the injected DC to host APC, and that host APC
can substantially contribute to OT-II cell proliferation.
Other Authors have reported minimal transfer of OVA from
injected DC to host DC [21]. To evaluate whether the amount of
OVA may underlie this discrepancy, we used a lower protein
concentration, 4 mg/ml, which is sufficient for good OT-II cell
proliferation in vitro. As this OVA concentration is insufficient for
cross-presentation by BM DC, DC were also loaded with
SIINFEKL to sensitize them to CTL-mediated killing. WT DC
loaded with SIINFEKL+OVA protein at 4 mg/ml induced robust
OT-II cell division in vivo, while MHCII
2/2 DC loaded with the
same amount of OVA induced undetectable responses (Figure 2E),
suggesting that presentation by host APC was insufficient for OT-
II cell proliferation. Interestingly, in these conditions, OT-I CTL
transfer significantly reduced, but did not ablate, OT-II T cell
proliferation (Figure 2E).
Taken together, these results suggest that CTL-mediated killing
of DC can significantly reduce the magnitude of CD4
+ T cell
responses, if antigen remains localized to the carrier DC (e.g.
peptide, low dose protein). In contrast, at high antigen doses, the
transfer of antigenic material from the injected DC to other APC
enables CD4
+ T cell proliferation to occur.
DC Killing and CD4
+ T Cell Responses
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37481Host DC can take up antigenic material from injected DC
in vivo and present it to CD4
+ and CD8
+ T cells in vitro
To obtain direct evidence of the transfer of material from
injected DC to host APC in vivo, CD45.1
+ DC were incubated with
DQ-OVA, which becomes fluorescent only after proteolytic
degradation, and injected into CD45.2
+ mice. As shown in
Figure 3A, at 24 h after transfer, DQ-OVA signal could be
detected in a CD45.2
+CD11c
+ host population in the dLN. This
population was not detected in mice injected with unlabelled DC.
Therefore, protein carried by the injected DC is taken up by host
DC.
Next, we asked if the material captured by host DC could be
presented to T cells in an immunostimulatory form. CD45.1
+ DC
loaded with 2 mg/ml OVA protein or no OVA were injected sub-
cutaneously (s.c.) into C57BL/6 mice, and 24 h later DC were
harvested from dLN and enriched by negative selection. Two DC
populations were prepared, a total DC population comprising
both host and donor DC, and a host-only DC population where
the CD45.1
+ injected DC were depleted by negative selection.
OVA presentation by these two DC populations was determined
by co-culturing DC with CFSE-labelled OT-I CD8
+ or OT-II
CD4
+ T cells for 3 or 5 days, respectively, and examining T cell
division by flow cytometry. As shown in Figure 3B, both the total
DC and the host-only DC populations induced proliferation of
CD8
+ and CD4
+ T cells, suggesting that host DC had taken up
antigenic material from injected DC and were able to present it in
an immunostimulatory form to T cells in vitro.
Host DC that take up OVA may cross-present it and become
susceptible to CTL-mediated killing in vivo. To address this
possibility, mice were injected with in vitro-activated OT-I CTL
before challenge with OVA-DC. DC populations were harvested
from dLN 1 day after DC injection and depleted of the injected
DC as in the experiment in Figure 3B. As shown in Figure 3C, the
ability of host DC to induce proliferation of OT-I T cells in vitro
was reduced by CTL transfer. This suggests that the number of
Figure 1. The form of antigen used for loading DC determines sensitivity to CTL-mediated killing in vivo. C57BL/6 mice were injected
i.v. with OT-I CTL and challenged s.c. 24 h later with a 1:1 mix of untreated CTO
+ DC (DC only), and CFSE
+ DC loaded with different forms of OVA.
Injected DC were recovered from the dLN 48 h later and quantified by flow cytometry. Representative flow cytometry plots from individual dLN are
shown on the left; the numbers of events in each gated region are shown. Bar graphs on the right show mean+SEM of OVA-specific DC killing for the
indicated groups of mice. (A) Killing of DC loaded with the OVA peptide SIINFEKL (SIINFEKL-DC). The bar graph shows combined results from two
experiments each including 2–3 mice per group. (B) Killing of DC endogenously expressing a membrane-associated form of OVA (OVAtg DC). The bar
graph shows the data from one of two independent experiments with 3 mice per group that gave similar results. (C) Killing of C57BL/6 or MHCII
2/2
DC loaded with OVA protein at 2 mg/ml (OVA-DC). The bar graph shows combined results from two experiments each including 2–3 mice per group.
doi:10.1371/journal.pone.0037481.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37481Figure 2. The impact of CTL-mediated killing of DC on CD4
+ T cell proliferation is determined by the form of antigen loaded on DC.
C57BL/6 mice were injected i.v. with CFSE-labelled, CD45-congenic OT-II cells; OT-I CTL were also injected in half of the mice at the same time. 24 h
later all mice were immunized s.c. with DC loaded with different forms of OVA. CD4
+ T cell proliferation in dLN was determined by flow cytometry 3
days after DC immunization. Representative flow cytometry histograms of CD45.1
+CD4
+ T cells from individual dLN are on the left of the bar graphs
for panels A and B, and below the bar graphs for panels C–E. The mean 6 SEM of the percent divided cells for the corresponding group is shown in
each panel. Bar graphs show mean+SEM of the number of divided CD45.1
+CD4
+ T cells per dLN. (A) CD4
+ OT-II T cell proliferation in mice immunized
with WT DC loaded with SIINFEKL and OVA323–339. The bar graph shows data from one of two independent experiments with 5 mice per group that
gave similar results. (B) CD4
+ OT-II T cell proliferation in mice immunized with OVAtg DC. The bar graph shows data from one of two independent
experiments with 5 mice per group that gave similar results. (C) CD4
+ OT-II T cell proliferation in mice immunized with WT DC or MHCII
2/2 DC loaded
with OVA protein at 2 mg/ml. The bar graph shows combined results from two independent experiments each including 5 mice per group. (D) CD4
+
OT-II T cell proliferation in mice immunized with WT or MHCII
2/2 DC loaded with SIINFEKL and OVA protein at 2 mg/ml. The bar graph shows results
from 5 mice per group. (E) CD4
+ OT-II T cell proliferation in mice immunized with WT or MHCII
2/2 DC loaded with SIINFEKL and OVA protein at 4 mg/
ml. The bar graph shows combined results from two independent experiments each including 5 mice per group.
doi:10.1371/journal.pone.0037481.g002
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presence of CTL.
Antigenic material from injected DC is taken up by host
DC in skin and LN
To identify the host DC subset that was presenting OVA from
the injected DC to T cells in vitro, host DC were purified by flow
sorting into a CD205
+CD8
lo skin-derived population, a
CD205
+CD8
hi LN-resident population, and a CD205
2CD8
2
(double negative) DC population, and each population was tested
for presentation of OVA to OT-I and OT-II cells in vitro. Host
skin-derived DC were dominant in presenting OVA to OT-I
CD8
+ T cells, and were the only subset tested that induced
proliferation of OT-II CD4
+ T cells (Figure 4A). LN-resident
CD8
+ DC induced proliferation of OT-I CD8
+ T cells, but not
OT-II CD4
+ T cells, while the double-negative DC populations
did not induce proliferation of either T cell population. We
conclude that OVA carried by injected DC is transferred to host
skin-derived DC, and can be presented by these cells to induce
CD4
+ T cell proliferation in vitro.
We wished to determine the site of OVA transfer from injected
DC to host skin DC, and used pertussis toxin (Ptx) to block DC
migration from the injection site to the dLN [22]. Preliminary
experiments showed that Ptx treatment did not affect DC viability,
and was effective at inhibiting DC migration to the dLN (data not
shown). Ptx-treated DC were loaded with a high dose of OVA,
2 mg/ml, and injected s.c. As shown in Figure 4B, OT-II T cell
proliferation after immunization with Ptx-treated DC was lower
than in mice immunized with untreated DC, but clearly detectable
and comparable in magnitude to the proliferation induced by
MHCII
2/2 DC loaded with the same amount of OVA. The
induction of OT-II T cell proliferation by MHCII
2/2 DC was
further decreased by Ptx treatment, but this decrease was not
statistically significant (Figure 4B). As Ptx-treated DC are unable
to reach the dLN, these results suggest that migration to the dLN is
not necessary for the transfer of antigenic material from injected
DC to host DC.
The differentiation of memory CD4
+ T cells is not
prevented by CTL-mediated DC killing
OT-I CTL did not inhibit the proliferation of OT-II T cells
after immunization with OVA-DC (Figure 2C). We wished to
determine whether this initial proliferation also resulted in the
generation of memory cells and ability to produce cytokines, and
therefore assessed IFN-c production by spleen CD4
+ cells 19 days
after DC immunization [23]. In mice immunized with WT DC
loaded with 2 mg/ml OVA, OT-II T cells were clearly detectable
in the spleen and approximately one quarter of these also
produced IFN-c upon in vitro restimulation. Neither the number
of OT-II cells nor their ability to produce IFN-c were affected by
transfer of OT-I CTL (Figure 5A). In contrast, as also reported by
other Authors [21], immunization with MHCII
2/2 DC induced
lower numbers of spleen OT-II cells compared to immunization
with WT OVA-DC, and only about 10% of these OT-II cells
produced IFN-c. Transfer of OT-I CTL did not affect either of
these responses (Figure 5A).
To test the effects of CTL on CD4
+ T cell responses under more
stringent conditions, we also used OVAtg DC as their numbers in
dLN were substantially reduced by CTL transfer (Figure 1B).
Again, CTL transfer did not affect the frequency of OT-II cells in
the spleen, nor their ability to produce IFN-c when restimulated in
vitro (Figure 5B). Thus, CTL-mediated DC killing does not impair
Figure 3. Host DC capture antigen from injected DC and
present to CD4
+ T cells in vitro. A) C57BL/6 mice were immunized
with CD45.1
+ DC loaded with DQ-OVA or no OVA. At 24 h after DC
injection, CD45.1
2CD45.2
+ host cells in the dLN were identified and
examined for CD11c expression and DQ-OVA uptake by flow cytometry.
Representative flow cytometry dot plots of live LN cells are shown on
the left and CD45.2
+ cells are shown on the right. The number of events
in each gate is shown. (B) C57BL/6 mice were injected with CD45.1
+ DC,
or CD45.1
+ DC loaded with OVA protein (2 mg/ml). The dLN were
collected 24 h later, and the total DC population (donor and host) and
CD45.1
2 DC population (host only) were magnetically purified and
cultured in triplicate with CFSE-labelled, purified OT-I or OT-II T for 3
days or 5 days, respectively. OVA-specific proliferation was evaluated as
CFSE dilution by flow cytometry. Each symbol shows mean+SEM of the
percentage of divided cells/well. Combined data from two independent
experiments that gave similar results are shown. (C) As in B, except that
some mice were injected i.v. with OT-I CTL 1 day before DC transfer, and
only host DC were tested. Symbols shows mean+SEM of the percentage
of divided cells/well. Combined data from two independent experi-
ments that gave similar results are shown.
doi:10.1371/journal.pone.0037481.g003
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immunization.
Pre-treating OVA-DC with Ptx to inhibit their migration to the
dLN also caused a reduction of both the number of OT-II cells in
the spleen, and their ability to produce IFN-c (Figure 5C). This
response was not significantly different from the response induced
by MHCII
2/2 DC. Thus, antigen presentation outside the dLN
was also not sufficient for the induction of IFN-c-producing OT-II
cells (Figure 5C).
Discussion
In this study we investigate the effects of CTL-mediated killing
of antigen-presenting DC on the development of CD4
+ T cell
responses. We used adoptive transfer of TCR transgenic T cells
and DC loaded with different forms of antigen to establish that
antigen-presenting DC injected in vivo were variably sensitive to
CTL-mediated killing, and that sensitivity to killing correlated with
the expected efficiency of MHCI/SIINFEKL complex formation.
Unexpectedly, we also observed that the ability of CTL to kill DC
in vivo was not sufficient to predict inhibition of CD4
+ T cell
responses. In conditions of high antigen loading, which permit
transfer of antigenic material from injected DC to host DC, OT-II
T cell proliferation and memory differentiation were preserved,
even if the injected DC appeared to be effectively cleared by CTL
and were not detected in the dLN.
Previous studies have examined the effects of CTL-mediated
killing of DC on CD4
+ T cell responses. Guarda et al. have
reported that CTL can suppress the proliferation of naı ¨ve CD4
+ T
cells after immunization with peptide-loaded DC [9], while
Laffont et al reported changes in the Th1/Th2 phenotype of
Figure 4. Antigen transfer from injected DC to host DC occurs at the site of DC injection. (A) C57BL/6 mice were injected with CD45.1
+ WT
DC or CD45.1
+ WT DC loaded with OVA protein (2 mg/ml). The dLN were collected 24 h later, and the CD8
+ DC, the CD8
2CD205
+ skin-derived DC
and the CD8
2CD205
2 double negative DC populations were sorted and cultured in duplicate with CFSE-labelled, purified OT-I or OT-II T for 3 days or
5 days, respectively. OVA-specific proliferation was evaluated as CFSE dilution by flow cytometry. Each symbol represents the mean+SEM of the
percentage of divided cells/well. Combined data from two independent experiments that gave similar results are shown. (B) C57BL/6 were injected
with CFSE-labelled CD45-congenic OT-II CD4
+ T cells and immunized 24 h later with WT or MHCII
2/2 DC that had been loaded with OVA protein
(2 mg/ml), and treated with Ptx or left untreated. CD4
+ T cell proliferation in dLN was determined by flow cytometry 3 days after DC immunization.
Representative flow cytometry histograms of CD45.1
+CD4
+ T cells from individual dLN are shown on the left. The mean 6 SEM of the percent divided
cells in each group is shown. The bar graph on the right shows mean+SEM of the number of divided CD45.1
+CD4
+ T cells/dLN. Combined results from
two independent experiments each with 5 mice per group are shown.
doi:10.1371/journal.pone.0037481.g004
DC Killing and CD4
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to extend those studies to DC loaded with antigen in different
forms and amounts, to establish the conditions in which DC are
affected by CTL-mediated killing. We observed that CD4
+ T cell
responses induced by immunization with peptide-loaded DC were
the most sensitive to the inhibitory effect of CTL, a results
presumably due to the combination of the high expression of
MHCI/SIINFEKL complexes at the cell surface, and consequent
efficient recognition by CTL, with a relatively inefficient transfer
of antigenic material to host APC. At the opposite end of the
spectrum, CD4
+ T cell responses induced by DC loaded with very
high amounts of OVA protein were only weakly affected by CTL.
This finding was only partly due to inefficient cross-presentation of
OVA on MHCI, as loading these DC with SIINFEKL peptide to
make them more sensitive to CTL-mediated killing was not
sufficient to fully restore the sensitivity of the CD4
+ response to
CTL-mediated inhibition, but reduced it to a level similar to that
observed after immunization with MHCII
2/2 DC (Figure 2D).
Thus, transfer of antigenic material from the carrier DC to host
APC appeared to play a key role in the generation of these
remaining CD4
+ T cell responses.
Transfer of antigenic material to host APC required high
antigen doses, which are unlikely to be available in vivo under
physiological situations. In contrast, lower OVA concentrations
(4–20 mg/ml) were insufficient for transfer, and could induce
CD4
+ T cell proliferation only if directly presented by carrier DC.
While these low OVA concentrations were not cross-presented by
the BM DC used in our study, they approach a range that can be
cross-presented by specialized DC populations, or if modified to
facilitate uptake [24], suggesting that DC loaded with physiolog-
ical amounts of antigen can be recognized and killed by specific
CTL. This possibility is supported by our recent data showing that
OVA-specific CTL can suppress Th2 effector responses in the
airway [16], presumably through killing of antigen-presenting DC.
Antigen transfer between injected DC and host DC has been
reported previously [21,25,26,27,28]. In line with those reports,
we show here that DQ-OVA, but also FITC-dextran or
intracellular labelling with CFSE or CTO (data not shown),
carried by injected DC could be detected in a small proportion of
host DC, providing evidence for the transfer of antigenic material
in vivo. Transwell experiments using OVAtg DC (not shown) also
indicated that antigen transfer did not require direct contact
between ‘‘carrier’’ and ‘‘host’’ DC, suggesting that it may be
mediated via transfer of cellular fragments or exosomes. Transfer
of MHC-peptide complexes has also been documented in other
studies [29]. While this DC ‘‘cross-dressing’’ would not be revealed
in the assays described above, it may also contribute to our
findings.
Host DC prepared from the dLN of mice injected with OVA-
DC could cross-present OVA to OT-I T cells in vitro. Similar
results were obtained also using SIINFEKL-DC (not shown),
suggesting that antigen and/or antigen-MHC complexes could
both transfer from injected DC to host DC. In line with those
observations, results in Figure 3C show that the stimulatory ability
of host DC was decreased by CTL transfer in vivo, presumably via
the killing of antigen presenting DC. Such killing is consistent with
our previous reports that antigen-specific CTL can inhibit the
expansion of naı ¨ve [5] and antigen-experienced [10] CD8
+ T cells
in vivo by killing antigen-presenting DC. However, CTL failed to
completely block CD4
+ T cell proliferation induced by DC loaded
with OVA protein (Figure 2B–E). These results suggest that, on a
per cell basis, some DC may escape CTL-mediated killing by
failing to simultaneously present antigen in the context of both
MHCI and MHCII.
Host skin-derived DC could present OVA to both CD4
+ and
CD8
+ T cells in vitro, whereas host LN-resident CD8
+ DC only
induced proliferation of OVA-specific CD8
+ T cells. The
observation that skin-derived host DC could present antigen from
injected DC suggests that antigen transfer was already occurring at
the site of DC injection in the skin. This conclusion is also
supported by experiments showing that host DC could stimulate
CD4
+ T cell proliferation in vivo, even when migration of the
injected DC to the dLN was inhibited using Ptx. These results
differ from previous studies where injected DC transferred their
antigens to host DC in the dLN [25], and suggest the existence of
multiple mechanisms of antigen exchange between DC popula-
tions. In contrast to MHCII, some MHCI-restricted antigen
transfer between migratory DC and CD8
+ DC also occurred in
the dLN. Transfer of antigen from tissue-derived migratory DC to
resident DC within the LN has been documented in a viral
infection model [30]. In our experiments, both skin-derived DC
and injected DC could potentially transport antigens to CD8
+ DC
because their migratory route through the lymphatics takes them
into the outer paracortex where CD8
+ DC reside [31,32]. We
have yet to determine which population is the source of this
antigen.
Immunization with antigen-loaded DC not expressing the
appropriate MHCII molecules has been shown to generate weak
Figure 5. Induction of IFN-c production by CD4
+ T is not
prevented by CTL-mediated DC killing. C57BL/6 mice were
injected with CD45-congenic OT-II CD4
+ T cells; OT-I CTL were injected
in some of the mice at the same time. 24 h later, mice were immunized
s.c. with DC loaded with different forms of OVA. 19 days after
immunization, spleens were collected and the total number of OVA-
specific, IFN-c-producing CD4
+ T cells was determined by intracellular
staining. Bar graphs show mean+SEM. (A) Mice were immunized with
WT or MHCII
2/2 DC loaded with OVA protein (2 mg/ml). The bar graph
shows data from one of two similar experiments, each with 5 mice per
group, that gave similar results. (B) Mice were immunized with OVAtg
DC. Results are from 5 mice per group. (C) Mice were immunized with
WT or MHCII
2/2 DC loaded with OVA protein (2 mg/ml); some of the
DC were also treated with Ptx. The bar graph shows data from 5 mice
per group.
doi:10.1371/journal.pone.0037481.g005
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+ T cell responses [21,25]. We also found that immunization
with MHCII
2/2 DC, or Ptx-treated DC, was sufficient for early
CD4
+ T cell proliferation in dLN, but did not induce memory
responses or IFN-c-producing OT-II T cells in spleen, possibly
suggesting that, after early division, OT-II T cells failed to fully
expand or underwent deletional tolerance. In contrast, CTL
transfer appeared to strongly reduce the accumulation of DC –
and hence direct antigen presentation – in dLN, but did not affect
CD4
+ memory formation or the generation of IFN-c-producing
OT-II T cells. The mechanism of this finding is not yet
established. CTL may not completely prevent the accumulation
of injected DC in the dLN, and DC numbers that are too low or
too transient to be detected in our experiments might still be
sufficient for full CD4
+ T cell responses. We think this is an
unlikely possibility: other Authors have reported that continued
antigen presentation is required for optimal CD4
+ T cell responses
in vivo [33,34,35]. Therefore, by itself, this scenario appears
unlikely to fully explain our results. A perhaps more likely
possibility is that host DC may co-operate with the few injected
DC that reach the dLN to induce full CD4
+ T cell responses.
CTL-derived cytokines induced by recognition of antigen on
injected DC [36] may support this process, perhaps by promoting
host DC maturation and migration to the dLN [37,38]. This
possibility is consistent with the observation that MHCII
2/2 DC
are unable to induce IFN-c responses regardless of the presence of
CTL. While cytokine exposure is not thought to be sufficient to
enable DC to induce effector differentiation of CD4
+ T cells [39],
it may provide sufficient signals for DC to support memory
development and some IFN-c production, as observed in our
experiments.
The importance of CTL and NK cell-mediated killing in the
regulation of DC survival and the control of immune responses is
consistent with observations that perforin deficiencies, which
dramatically affect cytotoxic function, are associated with immune
dysregulation and increased immune responses in mice and
humans [40,41]. Together with our recent work [16], data in this
paper suggest that DC killing can also affect, although variably,
CD4
+ T cell responses in vivo, possibly explaining why perforin
mutations are associated with accumulation of activated CD8
+ and
also CD4
+ T cells [42,43].
A better understanding of the conditions that control inhibition
vs. maintenance of T cell responses in the face of pre-existing CTL
and clearance of antigen-presenting DC will be important in the
understanding of how immune responses are maintained or
resolved, and in the design of protocols of DC administration for
the purpose of immunotherapy. Inter-DC antigen transfer has
been reported to result in tolerance induction in CD4
+ T cells in
the steady state [44], while in the context of a viral infection it may
lead to amplified CD8
+ immune responses [30]. Others have
reported that ‘cross-dressed’ DC, presenting pre-formed antigen-
MHCI complexes acquired from other cells, can activate memory
CD8
+ T cells [29], supporting the notion that inter-DC antigen
transfer can provide antigenic stimulation for memory T cells. We
look forward to studies where the physiological importance of
CTL-mediated DC killing and inter-DC antigen transfer is
thoroughly evaluated, and exploited for the purpose of improved
immunotherapies.
Materials and Methods
Ethics statement
All experimental protocols were approved by the Victoria
University Animal Ethics Committee (permits No. 2007R3M and
2010R2M) and performed in accordance with Institutional
guidelines.
Mice
All mice were bred and maintained at the Malaghan Institute of
Medical Research Biomedical Research Unit. C57BL/6 and
CD45-congenic B6.SJL-Ptprc
a were from the Animal Resources
Centre, Perth, Australia, and MHCII
2/2 B6Aa
0/Aa
0 [45] from
Dr. Horst Blu ¨thmann, Hoffmann-La Roche, Basel, Switzerland.
OT-I [46] and OT-II [47] mice carrying transgenic TCR specific
for K
b+OVA257–264 and I-A
b+OVA323–339, respectively, were
from Prof. F. Carbone, University of Melbourne, Melbourne,
Australia.
In vitro culture media and reagents
All cultures were in complete Iscove’s Modified Dulbecco
Medium (cIMDM) consisting of IMDM supplemented with 5%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 55 mM2 -
ME (all from Invitrogen, USA). Recombinant cytokines were
prepared from transfected cell lines and titrated using commercial
standards as a reference.
Cell lines and DC cultures
DC were generated from C57BL/6 BM or Nup98 HoxB4
OVAtg hematopoietic stem cells by culturing for 7 days in 10 ng/
ml murine rGM-CSF and 20 ng/ml murine rIL-4 as described
[48]. The Nup98 HoxB4 OVAtg haematopoietic stem cell line
was prepared from OVAtg mice [17] and maintained in culture as
described [49].
DC loading with antigen and injection in vivo
Non-adherent cells were harvested from GM-CSF/IL-4 cul-
tures on day 5 and incubated in fresh plates with the indicated
concentration of Grade V OVA (Sigma-Aldrich) for a further
48 h. In some experiments, endotoxin-free OVA (Profos AG,
Regensburg, Germany) or DQ-OVA (Molecular Probes, Invitro-
gen) were used. Lipopolysaccharide (LPS, Sigma-Aldrich) was
added at 100 ng/ml during the last 18–24 h of culture, after which
DC were washed and injected at 2610
5 cells/mouse. OVAtg DC
were activated with LPS and injected using these same conditions.
For peptide loading, LPS-treated DC were loaded with 1–
10 mM OVA257–264 (SIINFEKL) and/or OVA323–339 (ISQAV-
HAAHAEINEAGR) peptides (both from Mimotope, Australia) for
4 h at 37uC, and washed twice before injection. In some
experiments, DC were simultaneously treated with pertussis toxin
(List Biological Laboratories, Inc, USA) at 20 ng/ml for 2–3 h.
Peptide-loaded DC were resuspended in IMDM and injected at
1610
5 cells/mouse.
All DC were injected s.c. in the volar aspect of the anterior
forelimb. using a 29 G needle and a 0.3 ml syringe (BD
Biosciences, USA).
In vitro OT-I T cell activation and transfer
OT-I T cells were activated in vitro by culturing with DC and
0.1 mM SIINFEKL for 4 days, and expanded in 100 U/ml IL-2
for a further 2 days as described [50]. Greater than 95% of the
resulting T cells were Va2
+Vb5.1/5.2
+ and
CD8
+CD62L
loCD44
hi.5 610
6 OT-I CTL were transferred i.v.
into each mouse.
In vivo DC migration and cytotoxicity assays
LPS-treated GM-CSF/IL-4 DC were labelled with 1 mM CFSE
(Molecular Probes, USA) or 10 mM CTO (Molecular Probes) as
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6 of each population were
injected s.c. into the forelimb. At different times after injection,
brachial and axillary LN were harvested and digested with
100 mg/ml DNase I (Roche, USA) and 0.1 mg/ml Liberase CI
(Roche, USA) for 25 min and a subsequent 5 min with 10 mM
EDTA at 37uC. DC numbers in dLN were determined by flow
cytometry [7,10].
Enrichment and labelling of CD4
+ and CD8
+ T cells
Naı ¨ve OT-II and OT-I T cells were prepared from LN and
spleen cell suspensions and positively selected using anti-CD4 and
anti-CD8 magnetic beads (Miltenyi Biotech GmBH, Germany),
respectively. Enriched T cells were labelled with 1 mM CFSE for
10 mins at 37uC; labelling was stopped by adding FCS and
IMDM and cells were washed extensively before injection.
In vivo T cell proliferation
CFSE-labelled OT-II CD4
+ T cells were injected i.v. 24 h prior
to DC immunization. DC not loaded with OVA were included as
negative control in each experiment. Three days after DC
injection, OT-II CD4
+ T cell proliferation was assessed in the
pooled ipsilateral axillary and brachial LN using flow cytometry.
Ex vivo DC isolation and sorting
Ex vivo DC isolation and sorting were adapted from [51,52].
Brachial and axillary LN were digested with 100 mg/ml DNase I
and 0.3 mg/ml Liberase CI for 25 min at 37uC, followed by
EDTA (10 mM), and incubated with anti-FccRII/III (2.4G2) for
15–20 min at 4uC. Cell suspensions were then incubated with
biotinylated anti-CD3e (145-2C11), anti-NK1.1 (PK136), anti-
DX5 (DX5), anti-Ter119 (Ter119), anti-Thy1.2 (53-2.1) (all from
eBiosciences, USA), anti-CD19 (1D3), anti-Gr-1 (RB6-8C5) (BD
Pharmingen, USA) and anti-B220 (6B2; purified in-house) for
30 min at 4uC. In some experiments, biotinylated anti-CD45.1
(A20; eBiosciences) was also added. Antibody-labelled cells were
depleted using streptavidin magnetic beads and an AutoMACS
(both from Miltenyi Biotech GmBH, Germany) to obtain
populations that were 60–80% CD11c
+. To separate DC subsets,
CD11c
+ cells were first sorted on high CD11c expression (HL3;
BD Pharmingen), followed by sorting for CD205 (205yekta;
eBiosciences) and CD8 (53-6.7; BD Pharmingen) using a
FACSVantage SE (BD Biosciences). The purity of sorted DC
subsets was over 94%. Sorted DC were then cultured with CFSE-
labelled OT-I CD8
+ T cells or OT-II CD4
+ T cells for 3 or 5 days,
respectively, to evaluate antigen presentation.
In vitro T cell restimulation assays and intracellular
staining for cytokines
Spleens from immunized mice were digested with 100 mg/ml
DNase I and 0.1 mg/ml Liberase CI for 25 min, followed by
10 mM EDTA at 37uC; RBC were then lysed. Spleen cell
suspensions were plated in 6-well plates at 6610
6 cells/well in
cIMDM with or without 10 mM OVA323–339 and incubated for
15 h. After an additional 5 h incubation with GolgiStop (BD
Pharmingen) at 37uC, cells were surface labelled, permeabilized
with BD Cytofix/Cytoperm (BD Pharmingen) and labelled with
anti-IFN-c (XMG1.2; BD Pharmingen) or isotype control (R3-34;
BD Pharmingen). Cells were washed thrice with BD Perm/Wash
buffer before flow cytometry.
Flow cytometry analysis
Anti-FccRII/III receptor (2.4G2), anti-CD4 (GK1.5), anti-
CD8a (2.43) and anti-CD11c (N418) antibodies were affinity-
purified from hybridoma culture supernatants and conjugated to
allophycocyanin (APCy) as indicated. Anti-Va2-PE (B20.1), anti-
CD45.1-PE (A20), anti-CD4-FITC (GK1.5), anti-CD8a-APCy-
H7 (53-6.7), anti-IFN-c-APCy (XMG1.2) and Rat IgG1 k isotype-
APCy (R3-34) were from BD Pharmingen (USA). Anti-CD11c-
PE-Cy7 (N418), anti-CD45.1-PerCP-Cy5.5 (A20) and anti-
CD45.2 (104) conjugated to PE-Cy5.5, PE and APCy were from
eBiosciences (USA). Anti-CD45.2-Pacific blue (104) and anti-
CD11c-Alexa-Fluor 700 (N418) were from Biolegend (USA). All
samples were analysed on a FACSort, FACScalibur, or LSRII
SORP flow cytometer (BD Biosciences, USA) using CellQuest.
Dead cells were excluded from analysis using propidium iodide
(BD Pharmingen, USA) or DAPI (Molecular Probes, USA)
labelling. FlowJo version 9.0.2 (Treestar Inc, USA) was used for
analysis.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism
software using the Student’s t-test for comparison between two
groups, or one-way ANOVA with Bonferroni’s correction for
multiple group comparisons. Experimental data sets were tested
using the D’Agostino and Pearson omnibus test and shown to be
consistent with a Gaussian distribution. Means+SEM are shown in
all graphs; for the sake of clarity, one-sided error bars are shown.
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